Mammalian Cell Protein Expression — HEK293 & CHO Platform, 5,000+ Projects Delivered

Service Overview — AtaGenix’s mammalian cell expression platform has delivered 5,000+ projects and 200+ stable cell line constructions over 15 years. Offering HEK293 and CHO-S transient expression (mL to 100 L), stable cell line development (CHO-K1, DG44), and gram-scale recombinant antibody production, the system achieves native conformation, full glycosylation, and endotoxin <0.1 EU/mL in Class 100,000 cleanroom facilities — ISO 9001 & ISO 13485 certified.

Background: This study developed a trained immunity-related vaccine (TIrV) based on bacterial outer membrane vesicles (OMVs), targeting tumor-associated macrophages (TAMs) to overcome antigen dependence and immune tolerance limitations of traditional tumor vaccines.

AtaGenix’s Role: Expressed and purified SpyCatcher-RBD fusion protein via mammalian cells, enabling precise OMV surface modification with SIRPα-Fc via SpyTag/SpyCatcher ligation. The fully functional protein facilitated construction of OMV-SIRPα@CaP/GM-CSF nano-hybrids, driving myeloid progenitor training and TAM phagocytosis activation. Significant anti-tumor effects validated in MC38 and B16-F10 models.

Published in Advanced Materials (IF: 27.4) — DOI: 10.1002/adma.202306158

Fig. 1. OMV@CaP development and attenuated adverse effects. SpyCatcher-RBD fusion protein expressed by AtaGenix. Adapted from Adv Mater 2024.

Background: To overcome insufficient immunogenicity of RBD subunit vaccines, this study used icosahedral DNA origami (ICO) as a scaffold for virus-mimetic multimeric nanovaccines, optimizing B-cell activation efficiency.

AtaGenix’s Role: Expressed prototype RBD-SpyCatcher fusion and Omicron variant RBD (His-tagged) via mammalian cells, retaining native conformation with >85% loading efficiency onto DNA origami scaffolds. The nanovaccine (ICO-RBD) elicited potent humoral and T-cell immunity, with neutralizing titers significantly exceeding soluble RBD and cross-protection against multiple variants.

Published in Nature Communications (IF: 14.7) — DOI: 10.1038/s41467-024-53937-4

Fig. 2. Design and construction of ICO-RBD nanovaccines. RBD-SpyCatcher expressed by AtaGenix mammalian platform. Adapted from Nat Commun 2024.

Background: This study explored how meningeal autoreactive B cells drive neuroinflammatory relapse in the EAE mouse model, providing new therapeutic targets for multiple sclerosis (MS).

AtaGenix’s Role: Supplied recombinant mouse MOG protein with native-like conformation, enabling effective activation of autoreactive B–T cell cognate interactions in the meningeal microenvironment. The protein helped elucidate how meningeal B cells drive neuroinflammation via MHC II-mediated antigen presentation and GM-CSF-dependent neutrophil recruitment.

Published in Immunity (IF: 25.5) — DOI: 10.1016/j.immuni.2025.06.016

Fig. 3. Meningeal B cell interactions drive neuroinflammatory relapse. Recombinant mouse MOG protein provided by AtaGenix. Adapted from Immunity 2025.

Background: This work revealed the complement C3/C3aR pathway’s role in perioperative neurocognitive disorder (PND) in elderly patients, and explored platelet factor 4 (PF4) as a neuroprotective mechanism.

AtaGenix’s Role: Custom-expressed the C3-selective inhibitor CR2-crry protein via mammalian cells. The fully functional fusion protein precisely inhibited C3 activity, confirming that C3 blockade reduces glial activation, restores PF4 levels, and improves cognitive function — supporting ceftriaxone’s clinical potential for PND prevention.

Published in Molecular Psychiatry (IF: 9.6) — DOI: 10.1038/s41380-025-03103-z

Fig. 4. C3 blockage alleviates cognitive decline in PND mouse model. CR2-crry protein expressed by AtaGenix. Adapted from Mol Psychiatry 2025.

From recombinant protein production and antibody development to vaccine antigen preparation — AtaGenix’s mammalian expression platform delivers native-conformation, publication-grade proteins at any scale.

Response within 24 hours